Edition:
India

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

281.62USD
13 Sep 2019
Change (% chg)

$-2.56 (-0.90%)
Prev Close
$284.18
Open
$283.84
Day's High
$286.90
Day's Low
$279.59
Volume
242,194
Avg. Vol
297,982
52-wk High
$442.00
52-wk Low
$271.57

Latest Key Developments (Source: Significant Developments)

Sanofi: Libtayo (Cemiplimab) Approved For Advanced Cutaneous Squamous Cell Carcinoma In EU
Monday, 1 Jul 2019 

July 1 (Reuters) - SANOFI SA ::REG-SANOFI : LIBTAYO® (CEMIPLIMAB) APPROVED FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA IN THE EUROPEAN UNION.  Full Article

Libtayo Approved For Advanced Cutaneous Squamous Cell Carcinoma In EU
Monday, 1 Jul 2019 

July 1 (Reuters) - Regeneron Pharmaceuticals Inc ::LIBTAYO® (CEMIPLIMAB) APPROVED FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA IN EUROPEAN UNION.REGENERON PHARMACEUTICALS INC - EUROPEAN COMMISSION HAS GRANTED CONDITIONAL MARKETING AUTHORIZATION FOR LIBTAYO.REGENERON - AS PART OF CONDITIONAL APPROVAL, CO, SANOFI WILL ADD NEW PATIENT GROUP TO EMPOWER-CSCC-1 TO FURTHER SUPPORT BENEFIT-RISK PROFILE OF LIBTAYO.  Full Article

Regeneron Announces Positive Early-Stage Data For REGN1979 In Patients With B-Cell Non-Hodgkin Lymphoma
Friday, 14 Jun 2019 

June 14 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON CD20XCD3 BISPECIFIC REGN1979 SHOWS POSITIVE RESULTS IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, INCLUDING IN CAR-T FAILURES.REGENERON PHARMACEUTICALS - IN THIS TRIAL, TWO PATIENTS WHO FAILED CAR-T THERAPY AND RECEIVED REGN1979 80 MG ACHIEVED COMPLETE RESPONSES.REGENERON PHARMACEUTICALS - 93% OVERALL RESPONSE & 71% COMPLETE RESPONSE RATES IN FOLLICULAR LYMPHOMA GRADES 1 TO 3A TREATED WITH REGN1979 5 MG-320 MG.  Full Article

FDA Approves Eylea (Aflibercept) Injection For Diabetic Retinopathy
Tuesday, 14 May 2019 

May 13 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES EYLEA® (AFLIBERCEPT) INJECTION FOR DIABETIC RETINOPATHY.  Full Article

Regeneron Pharmaceuticals Q1 Non-GAAP Earnings Per Share $4.45
Tuesday, 7 May 2019 

Regeneron Pharmaceuticals Inc ::REGENERON REPORTS FIRST QUARTER 2019 FINANCIAL AND OPERATING RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $4.45.Q1 GAAP EARNINGS PER SHARE $3.99.Q1 EARNINGS PER SHARE ESTIMATE $5.46 -- REFINITIV IBES DATA.Q1 2019 REVENUES INCREASED 13% TO $1.71 BILLION VERSUS Q1 2018.Q1 REVENUE VIEW $1.76 BILLION -- REFINITIV IBES DATA.Q1 2019 EYLEA INJECTION U.S. NET SALES INCREASED 9% TO $1.07 BILLION VERSUS Q1 2018.ALSO CONTINUES TO INVEST IN A BROAD IMMUNO-ONCOLOGY PORTFOLIO.SEES 2019 CAPITAL EXPENDITURES $410 MILLION-$475 MILLION.SEES FY GAAP SANOFI COLLABORATION REVENUE $500 MILLION–$535 MILLION.QTRLY DUPIXENT NET PRODUCT SALES RECORDED BY SANOFI $373.7 MILLION VERSUS $131.4 MILLION.QTRLY PRALUENT NET PRODUCT SALES RECORDED BY SANOFI $63.9 MILLION VERSUS $59.9 MILLION.  Full Article

Regeneron Pharmaceuticals To Invest $800 Mln Through Upfront Cash And Equity Investment In Alnylam
Monday, 8 Apr 2019 

April 8 (Reuters) - Regeneron Pharmaceuticals Inc ::ALNYLAM AND REGENERON ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES.REGENERON PHARMACEUTICALS INC - TO INVEST $800 MILLION THROUGH UPFRONT CASH AND EQUITY INVESTMENT IN ALNYLAM.REGENERON PHARMACEUTICALS - CO, ALNYLAM TO ALSO JOINTLY ADVANCE SELECT NUMBER OF PRECLINICAL DISEASE PROGRAMS WITH TARGETS EXPRESSED IN LIVER.REGENERON PHARMACEUTICALS - $400 MILLION UPFRONT PAYMENT TO ALNYLAM, BUY $400 MILLION OF ALNYLAM EQUITY AT $90.00/SHARE FOR 4.44 MILLION ALNYLAM COMMON SHARES.REGENERON PHARMACEUTICALS INC - ALNYLAM WILL WORK EXCLUSIVELY WITH REGENERON TO DISCOVER RNAI THERAPEUTICS FOR EYE AND CNS DISEASES.REGENERON PHARMACEUTICALS - ALNYLAM ELIGIBLE TO GET ADDITIONAL $200 MILLION IN MILESTONE PAYMENTS UPON ACHIEVEMENT OF CERTAIN CRITERIA.REGENERON - TO LEAD DEVELOPMENT, COMMERCIALIZATION FOR ALL PROGRAMS TARGETING EYE DISEASES, WITH ALNYLAM ENTITLED TO POTENTIAL MILESTONE, ROYALTY PAYMENTS.  Full Article

FDA Approves Dupixent For Treatment Of Patients Aged 12 Years & Older With Moderate-To-Severe Atopic Dermatitis
Tuesday, 12 Mar 2019 

March 11 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS DUPIXENT APPROVED FOR TREATMENT OF PATIENTS AGED 12 YEARS AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.  Full Article

Regeneron's Supplemental Submission For Dupixent Wins FDA Approval
Tuesday, 12 Mar 2019 

March 11 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON PHARMACEUTICALS INC'S SUPPLEMENTAL SUBMISSION FOR DUPIXENT WINS FDA APPROVAL - FDA WEBSITE.  Full Article

Sanofi/Regeneron: FDA priority review of Dupixent for some adults with nasal polyps issues
Friday, 8 Mar 2019 

March 8 (Reuters) - Sanofi SA /Regeneron ::* The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent(®) (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP).* Patients with severe CRSwNP often experience recurrence despite previous treatment with surgery and/or systemic corticosteroids.* The target action date for the FDA decision is June 26, 2019..* Currently, there are no FDA-approved biologic medicines to treat CRSwNP, a chronic disease of the upper airway predominantly driven by type 2 inflammation and characterized by polyps that obstruct the sinuses and nasal passages.  Full Article

Sanofi Says CHMP Recommended Approval Of Dupixent For Asthma
Friday, 1 Mar 2019 

March 1 (Reuters) - Sanofi SA ::SANOFI: CHMP RECOMMENDS APPROVAL OF DUPIXENT® (DUPILUMAB) FOR ASTHMA INDICATION.SANOFI - EUROPEAN COMMISSION IS EXPECTED TO MAKE A FINAL DECISION ON APPLICATION FOR DUPIXENT IN COMING MONTHS.  Full Article

Photo

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.